Home › Genzyme And Isis Announce FDA Approval Of KYNAMRO (Mipomersen Sodium) Injection For The Treatment Of Homozygous Familial Hypercholesterolemia
 

Keywords :   


Genzyme And Isis Announce FDA Approval Of KYNAMRO (Mipomersen Sodium) Injection For The Treatment Of Homozygous Familial Hypercholesterolemia

2013-01-29 19:30:00| drugdiscoveryonline News Articles

Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for KYNAMRO (mipomersen sodium) injection

Tags: treatment approval injection announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Strategic use of soybean meal to maximize hog carcass weight during summer
26.06Eastern North Pacific Tropical Weather Outlook
26.06Atlantic Tropical Weather Outlook
26.06Aer Lingus pilots begin industrial action over pay dispute
25.06Water requirements in the summer
25.06New model Is transforming the study of liver abscesses in cattle
25.06Royal Mail buyer to make offer for all staff shares
25.06World's biggest music labels sue over AI copyright
More »